CoChat

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Open access
Gökbuget, N, Kelsh, M, Chia, V, Advani, A, Bassan, R, Dombret, H, Doubek, M, Fielding, A K, Giebel, S, Haddad, V, Hoelzer, D, Holland, C, Ifrah, N, Katz, A, Maniar, T, Martinelli, G, Morgades, M, O'Brien, S, Ribera, J-M, Rowe, J M, Stein, A, Topp, M, Wadleigh, M, Kantarjian, H · 2016 · Blood Cancer Journal
Cited by 125

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. Estimates of complete remission (CR) and overall survival (OS) were weighted by the frequency distribution of prognostic factors in the blinatumomab trial. Outcomes were also compared between the trial and historical data using propensity score methods. The historical cohort included 694 patients with CR data and 1112 patients with OS data compared with 189 patients with CR and survival data in the blinatumomab trial. The weighted analysis revealed a CR rate of 24% (95% CI: 20–27%) and a median OS of 3.3 months (95% CI: 2.8–3.6) in the historical cohort compared with a CR/CRh rate of 43% (95% CI: 36–50%) and a median OS of 6.1 months (95% CI: 4.2–7.5) in the blinatumomab trial. Propensity score analysis estimated increased odds of CR/CRh (OR=2.68, 95% CI: 1.67–4.31) and improved OS (HR=0.536, 95% CI: 0.394–0.730) with blinatumomab. The analysis demonstrates the application of different study designs and statistical methods to compare novel therapies for R/R ALL with historical data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2016.84

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 125

Metadata

Authors
Gökbuget, N., Kelsh, M., Chia, V, Advani, A., Bassan, R., Dombret, H., Doubek, M., Fielding, A. K., Giebel, S., Haddad, V, Hoelzer, D., Holland, C., Ifrah, N., Katz, A., Maniar, T., Martinelli, G., Morgades, M., O'Brien, S., Ribera, J.-M., Rowe, J. M., Stein, A., Topp, M., Wadleigh, M., & Kantarjian, H.
Venue
Blood Cancer Journal
Published
2016-09-23
Volume
6
Issue
9
Pages
e473-e473
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2521076777
Cited by
125
References
5
FWCI
10.28
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1038/bcj.2016.84
The paper
Gökbuget, N., Kelsh, M., Chia, V, Advani, A., Bassan, R., Dombret, H., Doubek, M., Fielding, A. K., Giebel, S., Haddad, V, Hoelzer, D., Holland, C., Ifrah, N., Katz, A., Maniar, T., Martinelli, G., Morgades, M., O'Brien, S., Ribera, J.-M., . . . Kantarjian, H. (2016). Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal. https://doi.org/10.1038/bcj.2016.84

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.